Lymphoma, Non Hodgkin Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • CD19/CD22 CAR T-Cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
N
Biospecimen Procurement for Genitourinary Malignancies Branch Immunotherapy Protocols
Recruiting
  • Multiple Myeloma
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-04-07
    Apr 7, 2022
    E
    A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
    Recruiting
    • Leukemia, Lymphoid
    • +6 more
    • Wuhu, Anhui, China
    • +21 more
    2022-04-06
    Apr 6, 2022
    N
    Tissue Collection for Studies of Lymph Cancer
    Recruiting
    • Hodgkin Disease
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-04-07
      Apr 7, 2022
      N
      Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
      Completed
      • Leukemia
      • +3 more
        • Bethesda, Maryland
          National Cancer Institute (NCI), 9000 Rockville Pike
        2022-04-07
        Apr 7, 2022
        C
        CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
        Recruiting
        • Lymphoma, Non-Hodgkin
        • +6 more
        • CB-010
        • +2 more
        • Scottsdale, Arizona
        • +5 more
        2022-04-05
        Apr 5, 2022
        P
        Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
        Enrolling by invitation
        • Lymphoma, B-Cell
        • +4 more
        • Burbank, California
        • +90 more
        2022-03-31
        Mar 31, 2022
        H
        A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
        Recruiting
        • Lymphoma, Non-Hodgkin
        • Melbourne, Victoria, Australia
        • +11 more
        2022-04-01
        Apr 1, 2022
        A
        A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
        Recruiting
        • Advanced Solid Tumor
        • +9 more
        • Phoenix, Arizona
        • +20 more
        2022-03-31
        Mar 31, 2022
        J
        GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma - 2022
        Completed
        • Lymphoma, Non-Hodgkin
        • Obinutuzumab and Pixantrone
        • Mainz, RLP, Germany
          Department of Hematology, Oncology and Pneumology; University Me
        2022-03-30
        Mar 30, 2022
        B
        Phase III Copanlisib in Rituximab-refractory iNHL
        Active, not recruiting
        • Lymphoma, Non-Hodgkin
        • Copanlisib (BAY 80-6946)
        • Jaú, Sao Paulo, Brazil
        • +20 more
        2022-03-25
        Mar 25, 2022
        J
        A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
        Recruiting
        • Lymphoma, Non-Hodgkin
        • Leukemia, Lymphocytic, Chronic, B-Cell
        • Birmingham, Alabama
        • +34 more
        2022-03-24
        Mar 24, 2022
        J
        A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
        Recruiting
        • Lymphoma, Non-Hodgkin
        • Leukemia, Lymphocytic, Chronic, B-Cell
        • New York, New York
        • +15 more
        2022-03-24
        Mar 24, 2022
        J
        A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
        Recruiting
        • Leukemia, Lymphocytic, Chronic, B-Cell
        • Lymphoma, Non-Hodgkin
        • Duarte, California
        • +49 more
        2022-03-24
        Mar 24, 2022
        J
        A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL
        Recruiting
        • Leukemia, Lymphocytic, Chronic, B-Cell
        • Lymphoma, Non-Hodgkin
        • New York, New York
        • +33 more
        2022-03-24
        Mar 24, 2022
        J
        A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
        Recruiting
        • Lymphoma, Non-Hodgkin
        • Chronic Lymphocytic Leukemia
        • New York, New York
        • +34 more
        2022-03-24
        Mar 24, 2022
        B
        Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
        Active, not recruiting
        • Lymphoma, Non-Hodgkin
        • Copanlisib (BAY80-6946)
        • +7 more
        • Chandler, Arizona
        • +200 more
        2022-03-23
        Mar 23, 2022
        H
        A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
        Recruiting
        • Lymphoma, Non-Hodgkin
        • Melbourne, Victoria, Australia
        • +1 more
        2022-03-21
        Mar 21, 2022
        E
        Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
        Recruiting
        • Leukemia, Lymphocytic, Chronic, B-Cell
        • +6 more
        • Miami, Florida
        • +4 more
        2022-03-07
        Mar 7, 2022
        T
        A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
        Recruiting
        • Lymphoma, Non-Hodgkin
        • Birmingham, Alabama
        • +54 more
        2022-03-17
        Mar 17, 2022
        A
        TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
        Recruiting
        • Lymphoma, Non-Hodgkin
        • +2 more
        • Birmingham, Alabama
        • +108 more
        2022-03-15
        Mar 15, 2022
        C
        A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
        Active, not recruiting
        • Lymphoma, Non-Hodgkin
        • Standard of Care
        • JCAR017
        • Phoenix, Arizona
        • +52 more
        2022-03-12
        Mar 12, 2022
        C
        Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
        Recruiting
        • Lymphoma, Non-Hodgkin
        • +2 more
        • Edmonton, Alberta, Canada
        • +9 more
        2022-03-14
        Mar 14, 2022
        M
        Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)
        Recruiting
        • Hodgkin Disease
        • +2 more
        • pembrolizumab
        • Favezelimab
        • Gilbert, Arizona
        • +24 more
        2022-03-07
        Mar 7, 2022
        U
        Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
        Active, not recruiting
        • Hodgkin Disease
        • +8 more
        • ATLCAR.CD30 cells
        • Chapel Hill, North Carolina
        • +1 more
        2022-03-02
        Mar 2, 2022